| Molecular Formula | C17H11ClN4O |
| Molar Mass | 322.75 |
| Density | 1.513±0.06 g/cm3(Predicted) |
| Boling Point | 511.0±50.0 °C(Predicted) |
| Solubility | DMSO: >3mg/mL at ~60°C, clear (with warming for 2 minutes) |
| Appearance | solid |
| Color | yellow |
| pKa | 11.75±0.43(Predicted) |
| Storage Condition | 2-8°C |
| In vitro study | PS-1145 blocks TNFalpha-induced NF-kappaB activation by inhibiting IkappaBalpha phosphorylation and IL-6 protects against Dex-induced apoptosis. PS-1145 also inhibited paracrine MM cell growth and IL-6 secretion caused by MM cell adhesion in BMSCs. In human primary CD4 (T) cells, PS-1145 abrogated cell proliferation and blocked the activation of nf-1b and AP-1 transcription factors through the participation of CD3 and CD28 co-receptors. |
| In vivo study | In male Wistar rats with DMBA-induced skin tumors, PS-1145 (50 mg/kg, I. v.) by upregulating p53, activating caspases, and down-regulating NF-κB and VEGF factors, tumor cell apoptosis is enhanced, thereby inducing tumor progression. |
| Hazard Symbols | Xn - Harmful![]() |
| Risk Codes | 22 - Harmful if swallowed |
| WGK Germany | 3 |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.527 ml | 12.637 ml | 25.274 ml |
| 5 mM | 0.505 ml | 2.527 ml | 5.055 ml |
| 10 mM | 0.253 ml | 1.264 ml | 2.527 ml |
| 5 mM | 0.051 ml | 0.253 ml | 0.505 ml |